Search

Your search keyword '"Jiang, Hanfang"' showing total 4 results
Start Over Author "Jiang, Hanfang" Publisher lippincott williams & wilkins
4 results on '"Jiang, Hanfang"'

4. Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report.

Author

Gui X, Li H, Song G, Shao B, and Jiang H

Subjects
Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Ductal pathology, Cisplatin administration & dosage, Female, Humans, Middle Aged, Thoracic Neoplasms pathology, Thoracic Wall drug effects, Thoracic Wall pathology, Treatment Outcome, Triple Negative Breast Neoplasms pathology, Vascular Endothelial Growth Factor A drug effects, Angiogenesis Inhibitors administration & dosage, Bevacizumab administration & dosage, Carcinoma, Ductal drug therapy, Carcinoma, Ductal secondary, Thoracic Neoplasms drug therapy, Thoracic Neoplasms secondary, Triple Negative Breast Neoplasms drug therapy
Abstract

Rationale: Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC., Patient Concerns: We reported a 49-year-old woman presenting with a giant breast tumor., Diagnoses: Stage IV TNBC with chest wall metastasis., Interventions: The patient underwent long-term use of bevacizumab combined with chemotherapy., Outcomes: The patient was on follow-up for 46 months, a remarkable improvement of the chest wall cutaneous lesion was observed., Lessons: Bevacizumab may provide benefits for TNBC patients with chest wall metastasis.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results